New Data Presented at ESTRO 2022 Reinforce Benefits of Accuray CyberKnife® and TomoTherapy® Platforms Across a Range of Indications and Complexities

More Than 70 Abstracts Build on the Clinical Evidence Supporting the Use of These Technologies SUNNYVALE, Calif., May 10, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that clinical studies continue to validate the versatility of the company's CyberKnife® and...

Click to view original post